Tagatose and galactose syrup

A tagatose and galactose syrup composition with a specific ratio, produced via enzymatic and filtration processes, addresses high production costs and crystallization issues, offering a cost-effective and efficient sweetener and prebiotic for various food products.

KR103046200B1Active Publication Date: 2026-11-10INALCO SPA
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
KR1020217013666
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-12
Filing Date
2019-10-10
Publication Date
2026-11-10
Estimated Expiration
2039-10-10

AI Technical Summary

Technical Problem

The use of crystalline tagatose as a food sweetener and prebiotic is limited due to high production costs, and sugar syrups tend to crystallize, leading to product loss and inefficiencies.

Method used

A composition comprising tagatose 40-50%, galactose 30-40%, oligosaccharides 7-10%, glycerol 4-10%, other sugars 2-8%, and trace amounts of lactose and lactulose, formulated as a syrup with a tagatose/galactose ratio of 1.0 to 1.6, produced through enzymatic hydrolysis, desugar reaction, epimerization, deionization, nanofiltration, and ultrafiltration to prevent crystallization and reduce production time.

Benefits of technology

The syrup composition offers a cost advantage, prevents crystallization, and enhances productivity, allowing its use in functional foods, sports drinks, and confectionery products while providing health benefits from tagatose and galactose synergies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112021052406510-PCT00001_ABST
    Figure 112021052406510-PCT00001_ABST
Patent Text Reader

Abstract

The present invention describes a syrup comprising tagatose and galactose as main components and containing small amounts of glycerol, oligosaccharides, and other sugars.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention relates to the field of sweeteners and prebiotics. Background Technology

[0002] Tagatose is a hexose ketone acid monosaccharide, an isomer of fructose, and is a rare sugar that is produced in small amounts when dairy products are heated.

[0003] Despite having 92% of the sweetness of sucrose, it reduces calorie intake (38%) and does not cause tooth decay, so it is used as a sweetener instead of regular sugar in the confectionery industry when making bakery products.

[0004] Tagatose has an antihyperglycemic effect because it regulates postprandial blood sugar levels by increasing the activity of glucokinase, an enzyme responsible for glucose transport within glycogen. It also reduces absorption by inhibiting certain enzymes involved in the breakdown of carbohydrates in the intestines.

[0005] Studies have been conducted on the effect of tagatose intake on reducing the glycemic index (Mark Ensor, et al. "Effect of triple low-dose administration of D-tagatose on glycemic control over 6 months in patients with mild type 2 diabetes mellitus" "Mellitus with Diet and Exercise" J Endocrinol Diabetes Obes. 2014 Oct; 2 (4) : 1057).

[0006] Therefore, tagatose is useful for the treatment of type 2 diabetes mellitus in which clinical studies have been conducted (ClinicanTrials.gov, NCT00955747, first published: August 10, 2009).

[0007] However, the use of crystalline tagatose as a food sweetener and as a prebiotic in foods and sports drinks is limited due to the cost of products that are not competitive compared to other synthetic or extracted molecules.

[0008] Galactose is a monosaccharide that is an epimer of glucose and is produced in small quantities in the human body, whereas most of it is introduced into the diet primarily through the consumption of milk and dairy products. It also contains lactose, a disaccharide that is broken down into glucose and galactose by the enzyme lactase. Lactose is the most abundant sugar in the breastfeeding of infants, who require an effective energy source as growing organisms, and it has been experimentally proven that galactose derived from it is involved in the process of myelin formation (Ravera S, Bartolucci M, Cazia D, Morelli A, Panfoli I, "Galactose and hexa-6-phosphate dehydrogenase assisting in myelin metabolism", PARIPEX Indian journal of research 2015, 4 (9) pp 21-24).

[0009] For example, various studies have been conducted on the positive effects of galactose on the central nervous system for the treatment of degenerative diseases such as Alzheimer's disease ("Therapeutic effects of oral galactose administration in a rat model of sporadic Alzheimer's disease," Alzheimer's & Dementia - The Journal of the Alzheimer's Association disease, July 2014, volume 10, issue 4, supplement page P464).

[0010] In addition, it has been experimentally proven that the intake of galactose and antioxidants may be useful in the treatment of multiple sclerosis, particularly in the early stages of the disease (Isabella Pandolfi, et al, "Supplementation of natural compounds halts progression of demyelinated brain: a case report", Medical Research Archives, vol. 4, issue 1, April 2016).

[0011] In addition, clinical studies on the use of galactose as a food supplement are currently underway in the treatment of congenital glycosylation disorders (ClinicanTrials.gov, NCT02955264, first published: November 4, 2016) and in the treatment of type 2 diabetes (ClinicanTrials.gov, NCT01776099, first published: January 25, 2013).

[0012] Oligosaccharides are known to have various properties beneficial to health, such as galacto-oligosaccharides formed by the action of the enzyme lactase (beta-galactosidase), which, in addition to having hydrolytic activity for lactose, performs a synthetic reaction that adds galactose units at variable values.

[0013] Galactooligosaccharides have a probiotic effect that promotes the growth of intestinal microorganisms (mainly Bifidobacteria), and according to several studies, they can inhibit the growth of potentially pathogenic microorganisms (Daniele Garrido, et al., "Utilization of galactooligosaccharides by Bifidobacterium longum isolated from infants", Food Microbiol. 2013 Apr. 33 (2); 262-270).

[0014] Therefore, the object of the present invention is to provide tagatose and galactose syrup and a method for manufacturing the same. The problem to be solved

[0015] The present invention solves the above-mentioned problem through a composition comprising the following components:

[0016] Tagatos 40-50%

[0017] Galactose 30-40%

[0018] Oligosaccharide (GLT) 7-10%

[0019] Glycerol 4-10%

[0020] Other sugars 2-8%

[0021] Lactose ≤ 1%

[0022] Lactotolos ≤1 %

[0023] The above tagatose / galactose ratio is 1.0 to 1.6, where % is weight % relative to the anhydrous composition, and the composition is in the form of a syrup having a sugar measurement concentration of 58 to 62° Brix. means of solving the problem

[0024] Accordingly, the object of the present invention is a syrup comprising tagatose and galactose as main components and containing small amounts of other secondary products such as glycerol, oligosaccharides, and other sugars. The composition of the present invention not only avoids the crystallization process of tagatose (which inevitably causes product loss in the mother liquor of crystallization) but also offers a final cost advantage by enabling a reduction in production time along with increased productivity.

[0025] Therefore, while it is clear that a syrup-type composition has advantages, one of the problems with sugar syrup is that it tends to crystallize depending on purity and storage conditions. However, the composition of the present invention has a compositional ratio of tagatose to galactose of 1.0 to 1.6, which is an undeniable advantage from a commercial perspective and in terms of product use, and surprisingly, it has been found to prevent the occurrence of such problems. Meanwhile, in addition to being for the intake of tagatose, the composition of the present invention allows for the introduction of other substances, such as galactose and galacto-oligosaccharides, which can exert synergistic effects for the reasons mentioned above, into the diet and also contributes positively to health.

[0026] Due to the beneficial effects of tagatose and galactose, the syrup of the present invention can be used in the manufacture of functional foods, medical foods, sports drinks, fruit juices, yogurts, and food supplements, as well as in the confectionery industry.

[0027] The object of the present invention is also a method for manufacturing the above-described syrup, wherein the method comprises:

[0028] i) enzymatically hydrolyze lactose using the enzyme lactase to obtain a mixture containing glucose and galactose;

[0029] ii) contact the above mixture containing glucose and galactose with at least one food yeast to perform a desugar reaction and obtain a desugar mixture;

[0030] iii) The above desugar mixture is subjected to an alkaline epimerization reaction to epimerize galactose into tagatose, thereby obtaining an epimerized mixture;

[0031] iv) The above epimerization mixture is brought into contact with one or more ion exchange resins to perform a deionization reaction and obtain a deionized mixture;

[0032] v) selectively nanofilter the above deionized mixture to obtain a nanofiltered mixture;

[0033] vi) selectively reverse osmotically treat the above deionized mixture or optionally nanofiltered mixture to obtain an osmotic residue;

[0034] vii) obtaining an ultrafiltered mixture by ceramic ultrafiltration of the above deionized mixture, optionally a nanofiltered mixture, or optionally an osmotic residue; and

[0035] viii) The above ultrafiltered mixture is treated to a concentration of up to 58 to 62° Brix to obtain a syrup. Brief explanation of the drawing

[0036] FIG. 1 illustrates an example of an HPLC chromatogram on a sulfonic column relating to a composition according to the present invention; FIG. 2 illustrates an example of an HPLC chromatogram on an amine column relating to a composition according to the present invention. Specific details for implementing the invention

[0037] In the syrup of the present invention, the tagatose / galactose ratio is preferably 1.1 to 1.5, more preferably 1.2 to 1.4.

[0038] The syrup of the present invention preferably has a sugar measurement concentration of 59 to 61° Brix.

[0039] The syrup of the present invention preferably has a pH of 3.0 to 3.5.

[0040] Preferably, the composition of the present invention comprises the following:

[0041] Tagathos 43-47%

[0042] Galactose 30-36%

[0043] Oligosaccharide (GLT) 7-10%

[0044] Glycerol 8-10%

[0045] Other sugars 2 ~ 5%

[0046] Lactose ≤ 1%

[0047] Lactulose ≤ 1 %

[0048] According to the method of the present invention, the raw material is preferably lactose monohydrate in crystalline form. Alternatively, other lactose sources such as whey may also be used.

[0049] The enzymatic hydrolysis step (i) of lactose is performed using commercially available lactase enzymes of various origins. For example, preferably derived from: K. lactis, K. fragilis, A. oryzae, A. niger, Escherichia coli, B. stearothermophilus, B. circulans, etc., and more preferably in the present invention, an enzyme of A. oryzae origin is used.

[0050] Lactase enzymes can be used in free and immobilized forms on various types of solid supports, and it is preferable to immobilize them on, for example, synthetic resins, alginate beads, synthetic membranes, or cotton fibers. In the present invention, it is preferable to use an immobilization enzyme on a polystyrene synthetic resin, and more preferably, an immobilization enzyme as described in patent application WO2014006606 is used.

[0051] The enzymatic hydrolysis reaction of lactose (i) is carried out at a temperature of 5 to 60 °C, preferably 52 °C and a pH of 4.0 to 9.0, preferably 5.1 to 5.5, and the lactose solution is maintained in a recirculating state on a column for 1 to 48 hours, preferably 20 hours.

[0052] According to the present invention, a solution containing lactose hydrolyzed into glucose and galactose undergoes a desugar step (ii) by adding food yeast, preferably freeze-dried brewer's yeast (S. cerevisiae), until the glucose concentration becomes 0.25% by weight or less. Specifically, the desugar reaction is carried out by maintaining the solution under air injection at a temperature of 25 to 40°C, preferably 30 to 37°C, more preferably 35°C, and a pH of 4.0 to 9.0, preferably 6.0 to 7.0, under stirring for at least 4 hours.

[0053] Galactose present in the desugar solution is converted to tagatose by an epimerization reaction (iii) by adding, for example, an alkaline substance, preferably sodium hydroxide, potassium hydroxide, or calcium hydroxide, and more preferably, calcium hydroxide is used according to the present invention. The alkaline substance is used in a molar ratio of 0.1 to 1.0, preferably 0.4 to 0.8, more preferably 0.6 moles per mole of galactose. The epimerization reaction (iii) is preferably carried out under stirring for at least 10 minutes, preferably 4 hours, at a temperature of preferably 0 to 30 ℃, preferably 5 to 25 ℃, more preferably 10 to 20 ℃.

[0054] Finally, the epimerization reaction (iii) is neutralized by adding an acid preferably selected from the group consisting of hydrochloric acid, phosphoric acid, and sulfuric acid, more preferably using 30 to 50 weight percent sulfuric acid dissolved in water. After neutralization with acid, the suspension is preferably centrifuged to separate the precipitated calcium sulfate and the residual yeast obtained from the desugar step.

[0055] The solution obtained after neutralization and centrifugation is a pair of ion exchange resins, preferably a strong cationic resin (e.g., Rohm and Haas Amberlite). TM 200 C, Rohm and Haas Amberlite TM IR120, Rohm, Haas Amberlite TM FPC 23 and Dowex TM Monosphere TM Pass it through 88), and then through a weak anionic resin (e.g., Dow ® Amberlite TM FPA 55, Dowex TM Monosphere TM 66, Rohm and Haas Amberlite TM IRA 96, Purolite ® A 120S and Purolite ® Deionize by passing it through A 109) (iv).

[0056] The deionized mixture may be subjected to nanofiltration (v) to optionally, but preferably, at least partially remove oligomeric components from polymers of dimer or higher. The nanofiltration is preferably performed, for example, by Dow Filmtec TMThe process is carried out on a spirally wound membrane selected from the group consisting of NF270-4040, Koch Membrane System TFC-SR2, or analogs thereof to recover the permeate, and the permeate is then, for the selective and preferably at least partially, glycerol is removed, e.g., and preferably Es. Dow Filmtec TM Reverse osmosis treatment is performed on a reverse osmosis membrane selected from the group consisting of BW 30-4040 (vi).

[0057] According to the present invention, the residue obtained in the reverse osmosis step (vi) is preferably purified by ultrafiltration (vii) in a ceramic membrane with a cutoff of 300,000 Da, and the permeate is recovered through a concentration step (viii). Preferably, an organic acid is added to correct the pH to a range of 3.0 to 3.5, and then the syrup is concentrated to obtain a syrup having a sugar measurement concentration of 60 ± 2°Bx. The organic acid is preferably selected from the group consisting of citric acid, lactic acid, and acetic acid. Preferably, the organic acid used for pH correction is citric acid, and more preferably, an aqueous solution of 40 to 60 weight% citric acid.

[0058] The present invention can be better understood according to the following examples.

[0059] Experimental section

[0060] HPLC Method:

[0061] Perkin Elmer 200 series chromatograph equipped with a refractive index detector and a temperature-controlled battery

[0062] Sulfone column analysis: Transgenomic ICE-SEP ION 300 column equipped with a pre-column. Temperature 45 ℃, flow rate 0.4 ml / min, eluent 0.015N sulfuric acid.

[0063] Amine column analysis: Thermo Scientific™ Hypersil™ APS-2. Temperature 40 ℃, flow rate 1.1 ml / min, mobile phase = acetonitrile + sodium phosphate monobasic dihydrate 1.45 g / L.

[0064] Example 1: Enzymatic hydrolysis of lactose on an industrial scale and acquisition of desugar solution

[0065] a) Preparation of enzymes immobilized in synthetic resin:

[0066] 10 m with temperature control function 3 750 liters of Purolite A 120 S resin were loaded into a steel jacketed reactor. The resin was washed three times with 750 liters of drinking water. 480 liters of a 100 mM sodium acetate solution with a pH of 5 and 55 kg of a 50% glutaraldehyde solution were added. After stirring the entire mixture at 25°C for 30 hours, the resin was washed three times with 1000 liters of drinking water. Next, 2000 liters of a 100 mM sodium acetate solution with a pH of 5 and 30 kg of lactase enzyme of A. oryzae were added. The entire solution was stirred at 25°C for 65 hours. Afterward, the resin was washed three times with 2000 liters of drinking water.

[0067] b) Enzymatic hydrolysis of lactose:

[0068] 2000 kg of crystalline lactose monohydrate in a 10 m² equipped with a stirring and temperature-controlled jacket 3 It was dissolved in 8,000 liters of drinking water in a steel reactor. 38 wt% sulfuric acid was added to adjust the internal temperature of the reactor to 53 ℃ and the pH to 5.39.

[0069] The lactose solution was recirculated for 20 hours at a flow rate of 2,400 liters / hour through a column containing 600 liters of resin (with immobilized lactase enzyme as described above in Example 1a).

[0070] Analysis results for the sulfone column:

[0071] Galactose (HPLC) 9.023 % Glucose (HPLC) 9.228 % Lactose (HPLC) 0.492 % Glucose / Galactose 1.02

[0072] Subsequently, the solution containing glucose and galactose is 20 m equipped with a stirrer and an air injection system 3 It was transferred to a steel jacketed reactor. The temperature was maintained at 35°C, and 12 kg of freeze-dried brewer's yeast and 100 ml of antifoaming agent (Silifood 1600) were added to the solution.

[0073] The solution was stirred at 35 ± 2 ℃ for 10 hours while injecting air into the entire solution. After stirring was finished, 9 liters of 30 wt% sodium hydroxide were added to restore the pH to 6.8. Once pH correction was complete, 10 kg of freeze-dried brewer's yeast was introduced into the reactor, and fermentation was maintained under stirring with air injected for an additional 10 hours. After stirring was finished, 15 liters of 30 wt% sodium hydroxide were added to adjust the pH to 6.6, and 10 kg of freeze-dried brewer's yeast was introduced. After an additional 15 hours had elapsed, the obtained desugar solution was cooled to approximately 5 ℃.

[0074] Analysis results for the sulfone column:

[0075] Galactose (HPLC) 8.058 % Glucose (HPLC) 0.013 % Lactose (HPLC) 0.491 % Glucose / Galactose 0.2

[0076] Example 2: Laboratory-scale epimerization reaction using 50 mol% calcium hydroxide relative to the molar amount of galactose at 40 °C, starting from the desugar solution of Example 1

[0077] 250 g of the desugar galactose solution prepared according to Example 1 was introduced into a 1-liter glass reactor, the temperature was controlled, a stirring rod was installed, and the entire solution was combined with 4.16 g of calcium hydroxide (ventilated lime) while stirring at a temperature of 40 ℃.

[0078] Samples were taken after 120, 240, and 360 minutes, respectively, for HPLC analysis on a sulfone column.

[0079] The results are shown in the following table:

[0080] Time (minutes) Gal / (Gal + Tag)*100 Tag / (Gal + Tag)*100 120 36 % 64 % 240 38 % 62 % 360 40 % 60 %

[0081] Example 3: Laboratory-scale epimerization reaction using 60 mol% calcium hydroxide relative to the molar amount of galactose at 40 °C, starting from the desugar solution of Example 1

[0082] 250 g of the desugar galactose solution prepared according to Example 1 was introduced into a 1-liter glass reactor, the temperature was controlled, a stirring rod was installed, and the entire solution was combined with 5.0 g of calcium hydroxide (ventilated lime) while stirring at a temperature of 40 ℃.

[0083] Samples were taken after 120, 240, and 360 minutes, respectively, for HPLC analysis on a sulfone column.

[0084] The results are shown in the following table:

[0085] Time (minutes) Gal / (Gal + Tag)*100 Tag / (Gal + Tag)*100 120 32 % 68 % 240 34 % 66 % 360 40 % 60 %

[0086] Example 4: Laboratory-scale epimerization reaction using 50 mol% calcium hydroxide relative to the molar amount of galactose at 30 °C, starting from the desugar solution of Example 1

[0087] 250 g of the desugar galactose solution prepared according to Example 1 was introduced into a 1-liter glass reactor, the temperature was controlled, a stirring rod was installed, and the entire solution was combined with 4.16 g of calcium hydroxide (ventilated lime) while stirring at a temperature of 30 ℃.

[0088] Samples were taken after 120 minutes, 280 minutes, and 350 minutes, respectively, for HPLC analysis on a sulfone column.

[0089] The results are shown in the following table:

[0090] Time (minutes) Gal / (Gal + Tag)*100 Tag / (Gal + Tag)*100 120 36 % 64 % 280 39 % 61 % 350 40 % 60 %

[0091] Example 5:Laboratory-scale epimerization reaction using 60 mol% calcium hydroxide relative to the molar amount of galactose at 30 °C, starting from the desugar solution of Example 1

[0092] 250 g of the desugar galactose solution prepared according to Example 1 was introduced into a 1-liter glass reactor, the temperature was controlled, a stirring rod was installed, and the entire solution was combined with 5.0 g of calcium hydroxide (ventilated lime) while stirring at a temperature of 30 ℃.

[0093] Samples were taken after 120 minutes, 280 minutes, and 350 minutes, respectively, for HPLC analysis on a sulfone column.

[0094] The results are shown in the following table:

[0095] Time (minutes) Gal / (Gal + Tag)*100 Tag / (Gal + Tag)*100 120 33 % 67 % 280 37 % 63 % 350 40 % 60 %

[0096] Example 6: Laboratory-scale epimerization reaction using 50 mol% calcium hydroxide relative to the molar amount of galactose at 25 °C, starting from the desugar solution of Example 1

[0097] 250 g of the desugar galactose solution prepared according to Example 1 was introduced into a 1-liter glass reactor, the temperature was controlled, a stirring rod was installed, and the entire solution was combined with 4.16 g of calcium hydroxide (ventilated lime) while stirring at a temperature of 25 ℃.

[0098] Samples were taken after 120, 280, 350, 470, 590, 710, and 790 minutes, respectively, for HPLC analysis on a sulfone column.

[0099] The results are shown in the following table:

[0100] Time (minutes) Gal / (Gal + Tag)*100 Tag / (Gal + Tag)*100 120 61 % 39 % 280 54 % 46 % 350 50 % 50 % 470 47 % 53 % 590 45 % 55 % 710 44 % 56 % 790 43 % 57 %

[0101] Example 7: Laboratory-scale epimerization reaction using 60 mol% calcium hydroxide relative to the molar amount of galactose at 25 °C, starting from the desugar solution of Example 1

[0102] 250 g of the desugar galactose solution prepared according to Example 1 was introduced into a 1-liter glass reactor, the temperature was controlled, a stirring rod was installed, and the entire solution was combined with 5.0 g of calcium hydroxide (ventilated lime) while stirring at a temperature of 25 ℃.

[0103] Samples were taken after 120, 280, 350, 470, 590, 710, and 790 minutes, respectively, for HPLC analysis on a sulfone column.

[0104] The results are shown in the following table:

[0105] Time (minutes) Gal / (Gal + Tag)*100 Tag / (Gal + Tag)*100 120 52 % 48 % 280 44 % 56 % 350 40 % 60 % 470 37 % 63 % 590 35 % 65 % 710 34 % 66 % 790 33 % 67 %

[0106] Example 8: Obtaining industrial-scale tagatose / galactose syrup starting from the desugar solution of Example 1

[0107] Alkaline epimerization reaction:

[0108] 9100 kg of desugar galactose solution prepared according to Example 1 was placed in a 10 m² device equipped with a stirrer and a temperature-controlled jacket. 3 It was introduced into a steel reactor. 192.4 kg of calcium hydroxide was added to a 30 wt% drinking water suspension (the amount of calcium hydroxide represented a molar ratio of 60 wt% relative to galactose). After addition, the temperature was maintained at 15 ± 5 ℃ under stirring. After completion, 590 liters of 38 wt% sulfuric acid were added while maintaining the temperature below 45 ℃ to maintain the pH of the suspension at 2.5. Then, the temperature was lowered to 25 ℃ and the precipitated calcium sulfate was separated by centrifugation eight times at 350 rpm for 25 minutes.

[0109] Analysis results for the sulfone column:

[0110] Tagatos (HPLC) 3.314 % Galactose (HPLC) 2.746 % Gal / (Gal + Tag)*100 45 % Tag / (Gal + Tag)*100 55 %

[0111] Deionization reaction on ion exchange resin:

[0112] The solution obtained from the previous centrifugation step is mixed at a flow rate of 2000 L / hour with a pair of ion exchange resins (400 L of strong cationic resin Amberlite). TM FPC 23 and 4000 liters weak anionic resin Amberlite TM The elution products from the resin were collected by deionizing treatment in FPA 55) with a sugar concentration ≥ 0.5°Bx and conductivity ≤ 50 μs / cm.

[0113] Nanofiltration:

[0114] Next, the deionized solution is applied to 12 membranes (DOW® FILMTECH) at a pressure of approximately 30 bar. TM The nanofiltration step was performed using a system composed of NF 270 (40 / 40).

[0115] Reverse osmosis:

[0116] The nanofiltration permeate passes through 12 membranes (DOW® FILMTECH) at a pressure of approximately 10 bar. TM Using a system composed of BW30-400, the reverse osmosis step was performed, and as a result, the residue was concentrated to a sugar concentration of 10° Bx.

[0117] Ceramic Ultrafiltration:

[0118] The concentrated solution was purified through a cross-flow ultrafiltration stage on a 300,000 Da co ceramic membrane at a permeation rate of 2,000 liters / hour, and the residue was recirculated at 9,000 liters / hour. The residue was concentrated to a maximum of about 300 liters and washed three times with 150 liters of drinking water each.

[0119] Concentration: The permeate purified in the previous ultrafiltration step was transferred to a 5,000-liter steel reactor equipped with a stirrer, a temperature-controlled jacket, and a condenser.

[0120] 1.6 liters of 50 wt% citric acid dissolved in water was added to the solution to adjust the pH to 3.0, and the solution was concentrated under vacuum at a temperature of about 50°C to a sugar measurement concentration of 60°Bx.

[0121] result:

[0122] The syrup obtained after the process was analyzed using sulfone and amine columns. The latter was analyzed to measure the lactose content (see HPLC traces in Figures 1 and 2), and the results are shown in the following table.

[0123] Refractive measurement dry material 60° Bx Tagathos 46.2% (anhydrous weight) Galactose 33.8% (anhydrous weight) Tagathos / Galactos B 1.3 Other substances Lactose 0.3% (anhydrous weight) Lactulos 0.4% (anhydrous weight) Glycerol 8.9% (anhydrous weight) Oligosaccharides (GLT) 8.0% (anhydrous weight) Other sugars 2.4% (anhydrous weight) pH 2.9 sulfuric acid ash 0.1 % density 1284 g / ml TAMC 5 ufc / g TYMC 0 ufc / g Salmonella sp. UFC-free 10g E. coli UFC / G No Content Enteric microbes UFC / G No Content

Claims

Claim 1 A composition comprising tagatose 40-50%; galactose 30-40%; oligosaccharide (GLT) 7-10%; glycerol 4-10%; other sugars 2-8%; lactose ≤ 1%; and lactotolos ≤ 1%, wherein the tagatose / galactose ratio is 1.0 to 1.6, where % is weight % relative to the anhydrous composition, and the composition is in the form of a syrup having a sugar measurement concentration of 58 to 62° Brix. Claim 2 A composition according to claim 1, wherein the tagatose / galactose ratio is 1.1 to 1.

5. Claim 3 A composition according to either claim 1 or 2, wherein the sugar measurement concentration is 59 to 61° Brix. Claim 4 A composition according to claim 1, wherein the pH is 3.0 to 3.

5. Claim 5 A composition according to claim 1 comprising or composed of tagatose 43-47%; galactose 30-36%; oligosaccharide (GLT) 7-10%; glycerol 8-10%; other sugars 2-5%; lactose ≤ 1%; and lactotolos ≤ 1%. Claim 6 A method for producing a syrup according to claim 1, comprising: i) enzymatically hydrolyzing lactose using a lactase enzyme to obtain a mixture containing glucose and galactose; and ii) contacting the above mixture containing glucose and galactose with at least one food yeast to perform a desugar reaction to obtain a desugar mixture; iii) subjecting the above desugar mixture to an alkaline epimerization reaction to epimerize galactose into tagatose and obtain an epimerized mixture; iv) contacting the above epimerized mixture with one or more ion exchange resins to perform a deionization reaction and obtain a deionized mixture; v) optionally nanofiltering the above deionized mixture to obtain a nanofiltered mixture; vi) optionally reverse osmosis treating the above deionized mixture or the optionally nanofiltered mixture to obtain an osmotic residue; vii) ceramic ultrafiltering the above deionized mixture, the optionally nanofiltered mixture, or the optionally reverse osmosis-treated osmotic residue to obtain an ultrafiltered mixture; and viii) treating the above ultrafiltered mixture to a concentration of up to 58 to 62° Brix to obtain a syrup, comprising the steps of: Claim 7 A manufacturing method according to claim 6, wherein the raw material is lactose monohydrate in crystalline form. Claim 8 A method of preparation according to claim 6, wherein the enzymatic hydrolysis reaction (i) of the lactose is carried out at a temperature of 5 to 60 ℃ and a pH of 4.0 to 9.0, the lactose solution is maintained in a recirculating state on a column for 1 to 48 hours, and the column comprises an immobilized lactase enzyme derived from K. lactis, K. fragilis, A. oryzae, A. niger, Escherichia coli, B. stearothermophilus, or B. circulans. Claim 9 A manufacturing method according to claim 6, wherein the desugar reaction is carried out by maintaining the mixture under air injection, at a temperature of 25 to 40 ℃ and a pH of 4.0 to 9.0, under stirring for at least 4 hours. Claim 10 A method of manufacturing according to claim 6, wherein the epimerization reaction (iii) is carried out by adding calcium hydroxide at a molar ratio of 0.1 to 1.0 per mole of galactose, and the epimerization reaction (iii) is carried out under stirring for 4 hours at a temperature of 0 to 30 ℃, and finally, the epimerization reaction (iii) is terminated by neutralizing treatment by adding 30 to 50 weight% of sulfuric acid dissolved in water, and after neutralization with acid, the suspension is centrifuged to separate the precipitated calcium sulfate and the yeast residue obtained from the desugar step. Claim 11 A composition according to claim 1 or 5 used in the manufacture of functional foods, medical foods, sports drinks, fruit juices, yogurts, and food supplements, and in the confectionery industry.

Citation Information

Patent Citations

  • Enzymes immobilised on styrene-divinyl benzene polymer matrices and the use thereof in industrial productions

    KR1020150041627A

  • Naturally-Sweetened Reduced-Calorie Base Syrup Compositions and Compositions Sweetened Therewith

    US20120189739A1

  • Ketose sugars from aldose sugars

    US4273922A